Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Denise Peterson

US Content Head, Pharma Insights

Washington, DC
Denise has had a colorful history reporting as a senior editor on numerous issues for publications now part of Informa's Pink Sheet and Scrip resources. Those include "The Pink Sheet", "The Blue Sheet" (NIH and public health programs), "The Beige Sheet" (medical technology reimbursement) and Medicare Drug Focus. Her areas of particular expertise include Capitol Hill and health care reimbursement. As US Content Head, she is inspired daily by the talented and knowledgeable US editorial team, and helps them provide the highest quality strategic insights for pharma's regulatory and commercial readers. She is based in Informa's flagship Washington, D.C. office.
Set Alert for Articles By Denise Peterson

Latest From Denise Peterson

Editor’s Choice: Notable Pink Sheet Articles From Q3

A must-read selection of intriguing and popular articles posted in the Pink Sheet over the past three months.

Clinical Trials Market Access

Policy Prescriptions: Kite's CAR-T; Price And Value Scrutiny; Biosimilars; Manufacturing Missteps

Kite's CAR-T application seems to be sailing ahead without US FDA AdComm review; large employers in the US look into value-based contracting while European regulators band together on joint price negotiations; Teva is back at FDA with its EpiPen application. Policy Prescriptions rounds up recent regulatory news and trends reported by sister publication the Pink Sheet.

Reimbursement Advisory Committees

Policy Prescriptions: Kite's CAR-T; Price And Value Scrutiny; Biosimilars; Manufacturing Missteps

Kite's CAR-T application seems to be sailing ahead without US FDA AdComm review; large employers in the US look into value-based contracting while European regulators band together on joint price negotiations; Teva is back at FDA with its EpiPen application. Policy Prescriptions rounds up recent regulatory news and trends reported by sister publication the Pink Sheet.

Reimbursement Advisory Committees

Policy Prescriptions: User Fees, EMA Worries, PBM Strategies, PRIME Milestones

The US has plenty of new pharma legislation, Europe has plenty of worries about EMA's Brexit move, pharmacy benefit managers give plenty more scrutiny to which products earn a place on formulary. Policy Prescriptions rounds up recent regulatory news and trends reported by sister publication the Pink Sheet.

Pharmacy Benefit Management Drug Review

Policy People In The News: Neomi Rao Confirmed To Head White House Reg Office

Former US FDA global regulator Howard Sklamberg joins law firm Akin Gump; PhRMA adds two VPS; more changes in personnel.

Appointments Policy

Rhetoric Meets Reality: A Timeline Of Trump's First 100 Days

President Trump is empty-handed on health care victories so far, as initial health reform repeal efforts collapsed and the shock value of drug pricing tweets wore off. But some actions may evolve into biopharma impact further down the road.

Policy FDA
See All
UsernamePublicRestriction

Register